Response to Comment on Feasibility of Raman spectroscopy as a potential in vivo tool to screen for pre-diabetes and diabetes

This letter aims to reply to Bratchenko and Bratchenko's comment on our paper Feasibility of Raman spectroscopy as a potential in vivo tool to screen for pre-diabetes and diabetes. Our paper analyzed the feasibility of using in vivo Raman measurements combined with machine learning techniques to screen diabetic and prediabetic patients. We argued that this approach yields high overall accuracy (94.3%) while retaining a good capacity to distinguish between diabetic (area under the receiver-operating curve [AUC] = 0.86) and control classes (AUC = 0.97) and a moderate performance for the prediabetic class (AUC = 0.76). Bratchenko and Bratchenko's comment focuses on the possible overestimation of the proposed classification models and the absence of information on the age of participants. In this reply, we address their main concerns regarding our previous manuscript.

Automated summary

This letter responds to Bratchenko and Bratchenko's comment on our paper examining the feasibility of using Raman spectroscopy and machine learning for screening pre-diabetes and diabetes. We address their concerns about potential overestimation of our proposed classification models and the lack of participant age information. Our research shows high overall accuracy (94.3%) in distinguishing diabetic and control groups, with moderate performance for the prediabetic class (AUC = 0.76).